$9.25
+0.40 (+4.52%)
Open$8.83
Previous Close$8.85
Day High$9.36
Day Low$8.83
52W High$23.57
52W Low$1.91
Volume—
Avg Volume388.2K
Market Cap275.67M
P/E Ratio9.24
EPS$2.29
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+202.1% upside
Current
$9.25
$9.25
Target
$27.94
$27.94
$24.18
$27.94 avg
$39.76
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 136.85M | 8.10M | 7.51M |
| Net Income | 75.94M | -2,253,266 | -2,377,750 |
| Profit Margin | 55.5% | -27.8% | -31.6% |
| EBITDA | 39.96M | -3,375,106 | -3,186,219 |
| Free Cash Flow | — | -1,035,116 | -1,228,536 |
| Rev Growth | +155.8% | +18.0% | -0.1% |
| Debt/Equity | 2.29 | 0.78 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |